A Phase 1 interventional study of Levetiracetam and Levetiracetam in Human Volunteers, sponsored by UCB Pharma. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-03.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The part A of N01362 is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to tablet oral administration in Chinese healthy volunteers.
The study includes 2 parts, part A is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to oral tablet, part B is to assess pharmacokinetic profile of LEV infusion during repeated dosing in Chinese healthy volunteers.
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
Drug: Levetiracetam
Levetiracetam oral tablet administered as one single dose.
Drug: Levetiracetam
Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
Also known as: Keppra
Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
Also known as: Keppra
Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable concentration (AUC(0-t))
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Area under the plasma drug concentration-time curve from 0 to infinity (AUC)
The area under the curve extrapolated to infinity is calculated as the sum of AUC(0-t) and a residual part extrapolated to infinite time.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Maximum measured plasma concentration (Cmax)
The value of the maximum plasma concentration is directly obtained from the observed plasma concentration versus time curves.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Area under the plasma drug concentration-time curve calculated from 0 to 12 h (AUC(0-12))
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Plasma concentration at the end of the 45-minutes intravenous (iv) infusion (C45'(iv))
The value of the plasma concentration at the end of the 45-min iv infusion is directly obtained from the experimental data of plasma concentration versus time curves.
Time frame: Pharmacokinetic samples were taken at 45 min after Levetiracetam administration
Time to reach the maximum plasma concentration of Levetiracetam after administration (tmax)
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Terminal half-life of Levetiracetam (t1/2)
The terminal half-life associated with the terminal rate constant λ_z is calculated as: ln2/λ_z. λ_z is the first order rate constant of elimination.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Total body clearance after intravenous infusion of Levetiracetam (CL(iv))
The CL(iv) is calculated as: CL=Dose of LEV/AUC.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Apparent total body clearance after oral administration of Levetiracetam (CL/F(tablet))
The CL/F (tablet) is calculated as: CL/F=Dose of LEV/AUC.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Volume of distribution after intravenous infusion of Levetiracetam (Vz(iv))
The volume of distribution after iv infusion is calculated as: Vz=CL/λ_z, where CL is the total body clearance and λ_z the first order rate constant of elimination.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
Apparent volume of distribution after oral administration of Levetiracetam (Vz/F(tablet))
The apparent volume of distribution after oral administration is calculated as: Vz/F= (CL/F)/λ_z.
Time frame: Pharmacokinetic samples were taken from pre-dose to 36 hours after Levetiracetam administration
The record gives a start of May 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam